Bioindustry Ethics.

Intro -- BIOINDUSTRY ETHICS -- BIOINDUSTRY ETHICS -- Contents -- Research Team -- Preface -- Acknowledgments -- Introduction -- ETHICAL ISSUES CONFRONTING BIOSCIENCE COMPANIES -- WHY SHOULD BIOSCIENCE FIRMS CARE ABOUT ETHICS? -- ETHICISTS AND THE BIOSCIENCE INDUSTRY -- A NEW APPROACH: BIOSCIENCE BUSINESS ETHICS -- STRUCTURE OF THE BOOK -- Merck: Staying the Course -- INTRODUCTION -- FOCUSING ON PATIENTS AND THE LONG TERM -- ETHICS RESOURCE CENTERS -- INTERNAL ETHICAL PRACTICES -- ASSESSING THE IMPACT -- BENEFITS OF AN ETHICAL APPROACH -- ETHICAL ISSUES -- DRUG PRICING, ACCESS, AND INTELLECTUAL PROPERTY -- CLINICAL TRIALS AND PUBLICATION OF RESULTS -- WHAT DRUGS TO DEVELOP -- CHALLENGES FOR THE FUTURE -- Genzyme: Putting Patients First -- INTRODUCTION -- PUTTING THE PATIENT FIRST: GENZYMEÌS APPROACH TO ETHICAL ISSUES -- ETHICAL ISSUES -- ETHICAL MECHANISMS -- SUSTAINING THE GENZYME CULTURE -- CONCLUSION -- Millennium pharmaceuticals, Inc.: Creating and Sustaining Corporate Values -- INTRODUCTION -- MILLENNIUM PHARMACEUTICALS INC. -- INSTITUTIONALIZING CORE VALUES AND ETHICS -- ETHICS EDUCATION PROGRAMS -- IMPACT OF INSTITUTIONALIZATION OF VALUES AND ETHICS -- PRESERVING A FOCUS ON CORE VALUES -- THE FUTURE -- Maxim Pharmaceuticals (A): Internal and External Dialogues -- AN UNUSUAL BIOTECH LEADER -- THE IMPACT OF BUSINESS ETHICS IN THE BIOSCIENCE INDUSTRY -- COMPANY HISTORY -- EMBEDDING CORE VALUES -- MECHANISMS FOR EMBEDDING CORE VALUES -- BUILDING A SUCCESSFUL GLOBAL BOARD -- ANNUAL STRATEGIC RETREAT -- DEALING WITH ETHICAL ISSUES -- MAXIM PHARMACEUTICALS (B) -- Diversa Inc.: Ethical Issues in Bioprospecting Partnerships -- FROM BIOPIRACY TO BIOPROSPECTING -- THE COMPANY -- THE CONTEXT FOR BIOPROSPECTING PARTNERSHIPS -- DIVERSAÌS BIODIVERSITY COLLABORATIONS -- PROCESS FOR ESTABLISHING AND IMPLEMENTING COLLABORATIVE AGREEMENTS.